Erin E. Karski

600 total citations · 1 hit paper
13 papers, 397 citations indexed

About

Erin E. Karski is a scholar working on Oncology, Neurology and Molecular Biology. According to data from OpenAlex, Erin E. Karski has authored 13 papers receiving a total of 397 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Oncology, 5 papers in Neurology and 4 papers in Molecular Biology. Recurrent topics in Erin E. Karski's work include Neuroblastoma Research and Treatments (5 papers), CAR-T cell therapy research (4 papers) and Sarcoma Diagnosis and Treatment (2 papers). Erin E. Karski is often cited by papers focused on Neuroblastoma Research and Treatments (5 papers), CAR-T cell therapy research (4 papers) and Sarcoma Diagnosis and Treatment (2 papers). Erin E. Karski collaborates with scholars based in United States, Italy and France. Erin E. Karski's co-authors include Steven G. DuBois, Surbhi Sidana, Olalekan O. Oluwole, Arun Balakumaran, Shahbaz A. Malik, Wade Lovelace, Jeffrey Matous, Sham Mailankody, Rajneesh Nath and Michaela Liedtke and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Erin E. Karski

13 papers receiving 390 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results

2023 168 citations Sham Mailankody, Jeffrey Matous et al. Nature Medicine profile →

Peers

Erin E. Karski

ONCOL

MB

PRM

IMMUN

HEMAT

Sasan Ghaffari Iran

H. A. Fritsche United States

Kristin Kathleen Ancell United States

Luis Fayad United States

Sami Ibrahimi United States

M Anzà Italy

Uwe Thiel Germany

Sylvie Daliphard France

Marc G. A. van Ijken Netherlands

Jacopo Olivieri Italy

Sasan Ghaffari Iran

Erin E. Karski

123 ×0.5

ONCOL

117 ×0.8

MB

36 ×0.4

PRM

84 ×1.1

IMMUN

40 ×0.5

HEMAT

Citations per year, relative to Erin E. Karski Erin E. Karski (= 1×) peers Sasan Ghaffari

Countries citing papers authored by Erin E. Karski

Since Specialization

Citations

This map shows the geographic impact of Erin E. Karski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Erin E. Karski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Erin E. Karski more than expected).

Fields of papers citing papers by Erin E. Karski

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Erin E. Karski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Erin E. Karski. The network helps show where Erin E. Karski may publish in the future.

Co-authorship network of co-authors of Erin E. Karski

This figure shows the co-authorship network connecting the top 25 collaborators of Erin E. Karski. A scholar is included among the top collaborators of Erin E. Karski based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Erin E. Karski. Erin E. Karski is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

1.

Mailankody, Sham, Jeffrey Matous, Saurabh Chhabra, et al.. (2023). Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results. Nature Medicine. 29(2). 422–429. 168 indexed citations breakdown →

2.

Mailankody, Sham, Jeffrey Matous, Michaela Liedtke, et al.. (2022). Universal Updated Phase 1 Data Highlights Role of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma. Blood. 140(Supplement 1). 4620–4622. 7 indexed citations

3.

Mailankody, Sham, Jeffrey Matous, Michaela Liedtke, et al.. (2020). Universal: An Allogeneic First-in-Human Study of the Anti-Bcma ALLO-715 and the Anti-CD52 ALLO-647 in Relapsed/Refractory Multiple Myeloma. Blood. 136(Supplement 1). 24–25. 57 indexed citations

4.

Siefker‐Radtke, Arlene O., Mayer Fishman, Arjun Vasant Balar, et al.. (2019). NKTR-214 + nivolumab in first-line advanced/metastatic urothelial carcinoma (mUC): Updated results from PIVOT-02.. Journal of Clinical Oncology. 37(7_suppl). 388–388. 18 indexed citations

5.

Campbell, Kevin, Erin E. Karski, Aleksandra Olow, et al.. (2017). Peripheral Blood Biomarkers Associated With Toxicity and Treatment Characteristics After 131 I- Metaiodobenzylguanidine Therapy in Patients With Neuroblastoma. International Journal of Radiation Oncology*Biology*Physics. 99(2). 468–475. 3 indexed citations

6.

Bourdeaut, Franck, et al.. (2017). ATRT-11. MARKED RESPONSE TO ATEZOLIZUMAB IN A PATIENT WITH RHABDOID TUMOR: A CASE STUDY FROM THE IMATRIX-ATEZOLIZUMAB TRIAL. Neuro-Oncology. 19(suppl_4). iv3–iv3. 6 indexed citations

7.

Geoerger, Birgit, Erin E. Karski, Michel Zwaan, et al.. (2017). A phase I/II study of atezolizumab in pediatric and young adult patients with refractory/relapsed solid tumors (iMATRIX-Atezolizumab).. Journal of Clinical Oncology. 35(15_suppl). 10524–10524. 9 indexed citations

8.

Edmondson, David A., Erin E. Karski, Ayano C. Kohlgruber, et al.. (2016). Transcript Analysis for Internal Biodosimetry Using Peripheral Blood from Neuroblastoma Patients Treated with 131I-mIBG, a Targeted Radionuclide. Radiation Research. 186(3). 235–235. 19 indexed citations

9.

Vo, Kieuhoa T., Erin E. Karski, Nicole Nasholm, et al.. (2016). Phase 1 study of sirolimus in combination with oral cyclophosphamide and topotecan in children and young adults with relapsed and refractory solid tumors. Oncotarget. 8(14). 23851–23861. 14 indexed citations

10.

Karski, Erin E., Mark R. Segal, Mark Krailo, et al.. (2015). Identification of Discrete Prognostic Groups in Ewing Sarcoma. Pediatric Blood & Cancer. 63(1). 47–53. 41 indexed citations

11.

Karski, Erin E., Christopher C. Dvorak, Wing Leung, et al.. (2014). Treatment of Hepatoblastoma With High-dose Chemotherapy and Stem Cell Rescue. Journal of Pediatric Hematology/Oncology. 36(5). 362–368. 9 indexed citations

12.

Imber, Brandon S., Aleksandra Olow, Erin E. Karski, et al.. (2014). Biomarker Modulations in Children With Neuroblastoma Following Treatment With 131I-mIBG. International Journal of Radiation Oncology*Biology*Physics. 90(1). S729–S730. 1 indexed citations

13.

Karski, Erin E., Katherine K. Matthay, John Neuhaus, Robert E. Goldsby, & Steven G. DuBois. (2012). Characteristics and outcomes of patients with Ewing sarcoma over 40 years of age at diagnosis. Cancer Epidemiology. 37(1). 29–33. 45 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact